Tideglusib as a First-in-Class Chemical Probe for NatA: Identification, Mechanism, and Cellular Validation of an Allosteric, CoA-Dependent Inhibitor
- 10 September 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (10) , 2712-2724
Abstract
N-terminal acetyltransferase A (NatA) catalyzes 40–57% of eukaryotic Nα-acetylation, a co-translational modification critical for protein stability, localization, and function, yet no validated small-molecule probe of NatA has been reported. Here, we describe the discovery and characterization of tideglusib (YD3139), a clinical-stage GSK-3β inhibitor, as the first small-molecule probe for NatA through a unprecedented catalysis-dependent mechanism. This dual-event mechanism was established through intact protein MS, rapid dilution assays, and substrate-independent IC50 profiling. Tideglusib binds allosterically to Saccharomyces cerevisiae NatA (yNatA), whereupon the CoA released during catalysis chemically modifies tideglusib to form a reversible covalent adduct, a new paradigm for acetyltransferase inhibition. Tideglusib was identified by screening of an in-house library (∼700 compounds) and confirmed by structural optimization of the thiadiazolidinedione scaffold, yielding IC50 values of 0.68–1.8 μM against yeast and human NatA with >20-fold selectivity over other NAT family members. Quantitative proteomics confirmed on-target suppression of NatA-mediated Nα-acetylation in yeast. These findings establish tideglusib as a mechanistic chemical probe for NatA, reveal NatA as a previously unrecognized molecular target for a promiscuous clinical-stage investigational compound, and introduce a conceptual framework for exploiting catalysis-dependent adduct formation as a new strategy for acetyltransferase inhibitor design.Keywords
Funding Information
- National Cancer Institute (P30 CA023168)
- National Cancer Institute (R01CA258887)
- National Institute on Aging (3RF1AG064250)
- National Institute of General Medical Sciences (R35GM118090)
- Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University
This publication has 37 references indexed in Scilit:
- Molecular mechanism of N-terminal acetylation by the ternary NatC complexStructure, 2021
- Structure and Mechanism of Acetylation by the N-Terminal Dual Enzyme NatA/Naa50 ComplexStructure, 2019
- Co-translational, Post-translational, and Non-catalytic Roles of N-Terminal AcetyltransferasesMolecular Cell, 2019
- Structure of Human NatA and Its Regulation by the Huntingtin Interacting Protein HYPKStructure, 2018
- 1,2,4-Thiadiazolidin-3,5-diones as novel hydrogen sulfide donorsEuropean Journal of Medicinal Chemistry, 2018
- A direct, ratiometric, and quantitative MALDI–MS assay for protein methyltransferases and acetyltransferasesAnalytical Biochemistry, 2015
- Nα-Acetylation of yeast ribosomal proteins and its effect on protein synthesisJournal of Proteomics, 2011
- Sequence requirements for Nα‐terminal acetylation of yeast proteins by NatAYeast, 2008
- Identification and characterization of genes and mutants for an N‐terminal acetyltransferase from yeast.The EMBO Journal, 1989
- Efficient synthesis of 1,2,4‐dithiazolidine‐3,5‐diones (dithiasuccinoyl‐amines) and observations on formation of 1,2,4‐thiadiazolidine‐3,5‐diones by related chemistryJournal of Heterocyclic Chemistry, 1984